(AOF) – Clinical Biotechnology Company Nanobiotix Announces Expiry of Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 Waiting Period for Global Licensing, Co-Development and Commercialization Agreement with Janssen Pharmaceutica NV (an entity of the Janssen Pharmaceutical Companies of Johnson & Johnson group) for the product candidate NBTXR3, a potential first-in-class radioenhancer. Following the expiry of this waiting period, the license agreement becomes effective and Nanobiotix is, as such, eligible for the payment of the upfront of 30 million dollars.
© 2023 Agence Option Finance (AOF) – All rights reserved by AOF. AOF collects its data from the sources it considers the most reliable. However, the reader remains solely responsible for their interpretation and for the use of the information made available to them. Thus the reader must hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends with the buttons below.
